The BBI ran a session on turning breakthrough health innovations into real world impact at SynBioBeta 2025, held from 5-8 May in San Jose, California.
The event brought together over 1,500 attendees from more than 50 countries, including scientists, entrepreneurs, investors, and policymakers, to explore the latest advancements in synthetic biology.
Key themes of the conference included AI & Digital Biology, Biomanufacturing Scale-Up, Human Health and Longevity, and Planetary Health.
The BBI team of Dr Kerstin Kinkelin, Dr Kathleen Sedgley, Prof Ash Toye and Prof Darryl Hill from University of Bristol, and Dr Francis Lister from Science Creates, were hosting a Lunch & Learn session to highlight the Bristol innovation ecosystem.
Ash showcased Scarlet Therapeutics (a University of Bristol spinout) and its therapeutic red blood cell technology, and Darryl presented a new, groundbreaking technology for rapid bacterial detection.
The conference was attended by a large delegation from the UK, including representatives from across the innovation ecosystem as well as former science minister and current Chair of the Regulatory Innovation Office, Lord David Willetts.
Thanks to everyone who attended and asked so many questions, and thanks to Fiona Mischel and John Cumbers from SynBioBeta for the opportunity to present.
